Montero Javier A, Ruiz-Moreno José M, Fernandez-Muñoz Marta
Vitreo-Retinal Unit, Alicante Institute of Ophthalmology, VISSUM, Alicante, Spain.
Eur J Ophthalmol. 2011 Jul-Aug;21(4):503-5. doi: 10.5301/EJO.2011.6290.
To report the anatomic and functional outcome of intravitreal bevacizumab (IVB) to treat choroidal neovascularization (CNV) following photodynamic therapy (PDT) to treat recurrent central serous choroidopathy (CSC).
This was an interventional case report in which verteporfin PDT was performed in a case of recurrent CSC.
Following PDT, the patient developed juxtafoveal CNV that was later treated by IVB, achieving CNV closure and recovery of visual acuity.
Photodynamic therapy is a useful therapy to treat recurrent CSC, though it may be associated with potentially severe complications such as CNV. Intravitreal bevacizumab seems a good alternative treatment in the management of this condition.
报告玻璃体内注射贝伐单抗（IVB）治疗复发性中心性浆液性脉络膜视网膜病变（CSC）接受光动力疗法（PDT）后脉络膜新生血管（CNV）的解剖学和功能结果。
这是一例介入性病例报告，对一例复发性CSC患者进行了维替泊芬光动力疗法。
光动力疗法后，患者出现黄斑旁脉络膜新生血管，随后接受玻璃体内注射贝伐单抗治疗，脉络膜新生血管闭合，视力恢复。
光动力疗法是治疗复发性CSC的有效方法，尽管可能会出现如脉络膜新生血管等潜在严重并发症。玻璃体内注射贝伐单抗似乎是治疗这种疾病的良好替代疗法。
